Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment Studies

被引:11
作者
Unger, Joseph M. M. [1 ]
LeBlanc, Michael [1 ]
George, Suzanne [2 ]
Wolmark, Norman [3 ,4 ]
Curran Jr, Walter J. J. [5 ]
O'Dwyer, Peter J. J. [6 ]
Schnall, Mitchell D. D. [7 ]
Mannel, Robert S. S. [8 ]
Mandrekar, Sumithra J. J. [9 ]
Gray, Robert J. J. [10 ]
Zhao, Fengmin [10 ]
Bah, Mariama [1 ]
Vaidya, Riha [1 ]
Blanke, Charles D. D. [11 ]
机构
[1] Fred Hutchinson Canc Ctr, SWOG Stat & Data Management Ctr, 1100 Fairview Ave N, M3-C102, POB 19024, Seattle, WA 98109 USA
[2] Brigham & Womens Hosp, Off Alliance Grp Chair, Boston, MA USA
[3] NRG Oncol, Philadelphia, PA USA
[4] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA
[5] Emory Univ, Dept Radiat Oncol, Atlanta, GA USA
[6] Univ Penn, Dept Med, Philadelphia, PA USA
[7] Univ Penn, Perelman Sch Med, Dept Genet, Philadelphia, PA USA
[8] Univ Oklahoma, Stephenson Canc Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Oklahoma City, OK USA
[9] Mayo Clin, Alliance Stat & Data Management Ctr, Dept Quantitat Hlth Sci, Rochester, MN USA
[10] Dana Farber Canc Inst, Imaging Network Biostat Ctr, Eastern Cooperat Oncol Grp, Amer Coll Radiol, Boston, MA USA
[11] Oregon Hlth & Sci Univ, SWOG Canc Res Grp Chairs Off, Knight Canc Inst, Portland, OR USA
基金
美国国家卫生研究院;
关键词
IMATINIB MESYLATE; ONCOLOGY; SURVIVAL;
D O I
10.1200/JCO.22.01826
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSEIn the United States, the National Cancer Institute National Cancer Clinical Trials Network (NCTN) groups have conducted publicly funded oncology research for 50 years. The combined impact of all adult network group trials has never been systematically examined.METHODSWe identified randomized, phase III trials from the adult NCTN groups, reported from 1980 onward, with statistically significant findings for & GE; 1 clinical, time-dependent outcomes. In the subset of trials in which the experimental arm improved overall survival, gains in population life-years were estimated by deriving trial-specific hazard functions and hazard ratios to estimate the experimental treatment benefit and then mapping this trial-level benefit onto the US cancer population using registry and life-table data. Scientific impact was based on citation data from Google Scholar. Federal investment costs per life-year gained were estimated. The results were derived through December 31, 2020.RESULTSOne hundred sixty-two trials comprised of 108,334 patients were analyzed, representing 29.8% (162/544) of trials conducted. The most common cancers included breast (34), gynecologic (28), and lung (14). The trials were cited 165,336 times (mean, 62.2 citations/trial/year); 87.7% of trials were cited in cancer care guidelines in favor of the recommended treatment. These studies were estimated to have generated 14.2 million (95% CI, 11.5 to 16.5 million) additional life-years to patients with cancer, with projected gains of 24.1 million (95% CI, 19.7 to 28.2 million) life-years by 2030. The federal investment cost per life-year gained through 2020 was $326 in US dollars.CONCLUSIONNCTN randomized trials have been widely cited and are routinely included in clinical guidelines. Moreover, their conduct has predicted substantial improvements in overall survival in the United States for patients with oncologic disease, suggesting they have contributed meaningfully to this nation's health. These findings demonstrate the critical role of government-sponsored research in extending the lives of patients with cancer.
引用
收藏
页码:2020 / +
页数:10
相关论文
共 35 条
[1]  
[Anonymous], CANC TRENDS PROGR RE
[2]  
[Anonymous], NAT CANC ACT 1971
[3]  
[Anonymous], 2021, Cancer Trends Progress Report
[4]  
[Anonymous], Cancer stat facts: Cancer disparities
[5]   Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 [J].
Blanke, Charles D. ;
Rankin, Cathryn ;
Demetri, George D. ;
Ryan, Christopher W. ;
von Mehren, Margaret ;
Benjamin, Robert S. ;
Raymond, A. Kevin ;
Bramwell, Vivien H. C. ;
Baker, Laurence H. ;
Maki, Robert G. ;
Tanaka, Michael ;
Hecht, J. Randolph ;
Heinrich, Michael C. ;
Fletcher, Christopher D. M. ;
Crowley, John J. ;
Borden, Ernest C. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :626-632
[6]   Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics [J].
Cronin, Kathleen A. ;
Lake, Andrew J. ;
Scott, Susan ;
Sherman, Recinda L. ;
Noone, Anne-Michelle ;
Howlader, Nadia ;
Henley, S. Jane ;
Anderson, Robert N. ;
Firth, Albert U. ;
Ma, Jiemin ;
Kohler, Betsy A. ;
Jemal, Ahmedin .
CANCER, 2018, 124 (13) :2785-2800
[7]   Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial [J].
DeMatteo, Ronald P. ;
Ballman, Karla V. ;
Antonescu, Cristina R. ;
Maki, Robert G. ;
Pisters, Peter W. T. ;
Demetri, George D. ;
Blackstein, Martin E. ;
Blanke, Charles D. ;
von Mehren, Margaret ;
Brennan, Murray F. ;
Patel, Shreyaskumar ;
McCarter, Martin D. ;
Polikoff, Jonathan A. ;
Tan, Benjamin R. ;
Owzar, Kouros .
LANCET, 2009, 373 (9669) :1097-1104
[9]   The Effect of Advances in Lung-Cancer Treatment on Population Mortality [J].
Howlader, Nadia ;
Forjaz, Goncalo ;
Mooradian, Meghan J. ;
Meza, Rafael ;
Kong, Chung Yin ;
Cronin, Kathleen A. ;
Mariotto, Angela B. ;
Lowy, Douglas R. ;
Feuer, Eric J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (07) :640-649
[10]  
IBM, IBM MICR WEB APPL AC